Law360, New York (June 22, 2010, 6:05 PM ET) -- An oral surgeon speaking on behalf of Merck & Co. on Tuesday told jurors in a trial concerning alleged risks of Fosamax that he would not generally advise patients to stop taking the osteoporosis drug if they complained of the jaw symptoms at issue in the case.
New York University professor of oral maxillofacial surgery Robert S. Glickman testified in the U.S. District Court for the Southern District of New York that he would not want to interfere with prescriptions for serious underlying conditions, such as...
Jaw Issues Not A Reason To Stop Fosamax: Expert
To view the full article, take a free trial now.
